Subject: Küsimus/Ravimiregister ja ATC-kood - RINVOQ
From: "Karbus, Kairit" <[email-masked]>
To: "Ravimiamet" <[email-masked]>
Date: Wed, 3 Apr 2024 09:05:53 +0300

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu
saatja korral palume linke ja faile mitte avada.

Tere!

Märkasime, et ravimil RINVOQ (upadatsitiniib) on ravimiregistris ja SPC-s
erinev ATC kood.

Kas oleks palun võimalik seda kontrollida.

Ette tänades

Kairit Karbus

Heade soovidega / Kind regards,

  _____

KAIRIT KARBUS

Regulatory Affairs Manager

Abbvie Estonia

AbbVie OÜ

Rävala pst.4

10145 Tallinn

Estonia

CELL         +372 5088264

EMAIL   <mailto:[email-masked]> [email-masked]

This communication may contain information that is proprietary,
confidential, or exempt from disclosure. If you are not the intended
recipient, please note that any other dissemination, distribution, use or
copying of this communication is strictly prohibited. Anyone who receives
this message in error should notify the sender immediately by telephone or
by return e-mail and delete it from his or her computer.

  _____